Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period ending June 30, 2024 [1] Group 1 - The significant reduction in net loss is primarily attributed to the sales of the Vita Flow Liberty transcatheter aortic valve and its delivery system in over 20 countries, resulting in more than a twofold increase in overseas revenue compared to the six months ending June 30, 2024 [1] - The commercial progress of the Anchor Man left atrial appendage occluder system and its delivery system in China has been steady, achieving CE marking and commercialization in Europe during the reporting period, contributing to revenue growth [1] - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]